Six-month sirtuin activator supplementation for women with overweight or obesity
Assessment of the Effect of Sirtuin Activator Supplementation on Cellular, Metabolic and Anthropometric Parameters in Women
NA · Poznan University of Life Sciences · NCT07245979
This test will see if taking a daily sirtuin activator supplement for six months improves metabolism in women aged 40–65 with overweight or obesity.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 40 Years to 65 Years |
| Sex | Female |
| Sponsor | Poznan University of Life Sciences (other) |
| Locations | 1 site (Poznan) |
| Trial ID | NCT07245979 on ClinicalTrials.gov |
What this trial studies
Women aged 40–65 with BMI over 25 will take either a sirtuin activator supplement or a placebo each day for six months. Researchers will compare the two groups on lipid and carbohydrate metabolism as well as measures of oxidative stress, immune function, and cellular ageing. Participants will visit the university every three months for checkups and laboratory tests. The study compares outcomes between the supplement and placebo arms to determine whether the supplement produces measurable metabolic improvements.
Who should consider this trial
Good fit: Women aged 40–65 with overweight or obesity (BMI >25 kg/m2) who are not pregnant or breastfeeding and are not using weight-loss, diabetes, or lipid-lowering medications are ideal candidates.
Not a fit: Men, people with BMI under 25, individuals with diabetes, recent bariatric surgery, major chronic kidney, liver, autoimmune disease or cancer, current alcohol addiction, recent sirtuin activator use, or those who are pregnant or breastfeeding are unlikely to benefit or may be ineligible.
Why it matters
Potential benefit: If effective, the supplement could improve lipid and glucose metabolism and reduce oxidative stress in middle-aged women with excess weight.
How similar studies have performed: Small human studies of sirtuin activators have reported mixed metabolic effects, so the approach is promising but not yet proven in larger trials.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * females * age: 40-65 years * overweight or obese: BMI \>25 kg/m2 Exclusion Criteria: * males * BMI \< 25 kg/m2 * sirtuin activators administration for 3 months prior to study * pregnancy or breastfeeding * recent dieting or being on calorie restricted diet * receiving pharmacotherapy to treat obesity, diabetes or hyperlipidemia * post-bariatric surgery * diabetes * cancer * chronic kidney, liver or autoimmune diseases * alcohol addiction
Where this trial is running
Poznan
- Poznan University of Life Sciences — Poznan, Poland (RECRUITING)
Study contacts
- Principal investigator: Agata Chmurzynska, Professor — Poznan Univeristy of Life Sciences
- Study coordinator: Agata Chmurzynska, Professor
- Email: agata.chmurzynska@up.poznan.pl
- Phone: +486184661
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Obesity & Overweight